Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PSB202 |
Synonyms | |
Therapy Description |
PSB202 is comprised of an anti-CD20 monoclonal antibody and an anti-CD37 monoclonal antibody, which potentially induces B-cell killing and tumor reduction (Cancer Res 2022;82(12_Suppl):Abstract nr 2902). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PSB202 | PSB-202|PSB 202 | CD20 Antibody 24 CD37 Antibody 8 | PSB202 is comprised of an anti-CD20 monoclonal antibody and an anti-CD37 monoclonal antibody, which potentially induces B-cell killing and tumor reduction (Cancer Res 2022;82(12_Suppl):Abstract nr 2902). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Unknown status | USA | AUS | 1 |